Assertio Therapeutics (ASRT)
NASDAQ:ASRT
Want to see ASRT full AI Analyst Report?
ASRT Stock Chart & Stats
$18.01
-$0.03(-3.72%)
At close: 4:00 PM EST
$18.01
-$0.03(-3.72%)
Day’s Range― - ―
52-Week Range$8.61 - $23.46
Previous CloseN/A
Volume363.47K
Average Volume (3M)414.05K
Market Cap
$151.47M
Enterprise Value$158.07M
Total Cash (Recent Filing)$71.57M
Total Debt (Recent Filing)$40.31M
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Jul 30, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.54
Shares Outstanding6,462,180
10 Day Avg. Volume336,400
30 Day Avg. Volume414,050
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.62
Price to Sales (P/S)0.49
P/FCF Ratio-2.06
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue1.55
Enterprise Value/Gross Profit3.49
Enterprise Value/Ebitda41.33
Forecast
1Y Price Target
$24.20Price Target Upside34.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.5
Revenue Forecast (FY)$105.86M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~70% gross margins reflect strong product-level economics typical of branded specialty pharma. Durable margin structure gives room to absorb SG&A, support EBITDA expansion, and fund commercialization of Rolvedon without proportional COGS pressure, aiding long-term profitability recovery.
Rolvedon Demand And Long Patent LifeRolvedon (Rovodon) is positioned as the company’s core durable asset: clear underlying demand growth (~32% YoY) and patent/IP protection into 2039 create a multi-year revenue runway. This structural product strength supports predictable cash flow and underpins management's growth guidance.
Take-private Acquisition Provides Strategic CertaintyA committed acquirer and planned tender offer represent a structural change that can de-risk public-market volatility, enable longer-term operational planning, and allow coordinated capital actions (note repurchases, minimum cash conditions). This may strengthen funding and execution certainty for Rolvedon commercialization.
Bears Say
Multi-year Revenue Decline & LossesA sustained revenue downtrend and reversion to negative operating and net results indicate structural demand or portfolio weaknesses. Persistent losses impair reinvestment capacity, elevate execution risk for commercialization plans, and challenge restoration of returns and shareholder equity over the medium term.
Weak Cash Generation And Working-capital StrainNegative operating and free cash flow and a large sequential cash decline driven by working-capital build reduce financial flexibility. Even if management expects normalization, continued cash deficits would limit investments, increase refinancing risk, and make execution on commercialization and SG&A savings harder to sustain.
Concentration Risk After Divestiture And Generic ErosionDivesting non-Rolvedon products concentrates revenue into a single franchise while legacy assets like Indocin face further generic erosion. This raises single-product risk: business outcomes and cash generation now hinge primarily on Rolvedon adoption, exclusivity, and pricing dynamics.
Assertio Therapeutics News
ASRT FAQ
What was Assertio Therapeutics’s price range in the past 12 months?
Assertio Therapeutics lowest stock price was $8.61 and its highest was $23.46 in the past 12 months.
What is Assertio Therapeutics’s market cap?
Assertio Therapeutics’s market cap is $151.47M.
When is Assertio Therapeutics’s upcoming earnings report date?
Assertio Therapeutics’s upcoming earnings report date is Jul 30, 2026 which is in 60 days.
How were Assertio Therapeutics’s earnings last quarter?
Assertio Therapeutics released its earnings results on May 08, 2026. The company reported -$2.93 earnings per share for the quarter, missing the consensus estimate of -$2.102 by -$0.828.
Is Assertio Therapeutics overvalued?
According to Wall Street analysts Assertio Therapeutics’s price is currently Undervalued.
Does Assertio Therapeutics pay dividends?
Assertio Therapeutics does not currently pay dividends.
What is Assertio Therapeutics’s EPS estimate?
Assertio Therapeutics’s EPS estimate is -0.36.
How many shares outstanding does Assertio Therapeutics have?
Assertio Therapeutics has 6,462,180 shares outstanding.
What happened to Assertio Therapeutics’s price movement after its last earnings report?
Assertio Therapeutics reported an EPS of -$2.93 in its last earnings report, missing expectations of -$2.102. Following the earnings report the stock price went up 0.581%.
Which hedge fund is a major shareholder of Assertio Therapeutics?
Currently, no hedge funds are holding shares in ASRT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Assertio Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$24.20 (34.37% Upside)
$24.20 (34.37% Upside)
Blogger Sentiment
Bearish
ASRT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 5.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 16.6%
Last 30 Days ▼ 16.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
130.25%
12-Months-Change
Fundamentals
Return on Equity
-38.72%
Trailing 12-Months
Asset Growth
-26.23%
Trailing 12-Months
Company Description
Assertio Therapeutics
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
ASRT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a constructive long-term outlook centered on Robodon: integration is complete, FY2025 results beat guidance, margins and adjusted EBITDA improved year-over-year, and management provided 2026 guidance that anticipates profitability expansion. However, material near-term challenges remain — notably the large Q4 revenue decline and negative Q4 adjusted EBITDA driven by a timing-driven sell-in, a significant sequential cash reduction due to working capital, and ongoing erosion risk in legacy products (Indocin) from generic competition. Management frames many negatives as temporary (sell-in timing, working capital) and emphasizes durable improvements (commercial platform, cost reductions, Robodon secular demand). Balancing the substantial positive catalysts and guidance against the short-term execution and cash pressures yields an overall positive outlook conditional on Robodon demand and normalization of working capital.View all ASRT earnings summariesASRT Stock 12 Month Forecast
Average Price Target
$24.20
▲(34.37% Upside)
Technical Analysis
Ownership Overview
5.11% Insiders
12.00% Mutual Funds
20.11% Other Institutional Investors
58.45% Public Companies and
Individual Investors